HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Addonizio, V. P. Articles by Edmunds, L. H. Search for Related Content PubMed PubMed Citation Articles by Addonizio, V. P., Jr Articles by Edmunds, L. H., Jr

The Journal of Thoracic and Cardiovascular Surgery, Vol 89, 926-933, Copyright © 1985 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Iloprost (ZK36374), a stable analogue of prostacyclin, preserves platelets during simulated extracorporeal circulation

VP Addonizio Jr, CA Fisher, BK Jenkin, JF Strauss 3d, JF Musial and LH Edmunds Jr

Contact between blood and synthetic surfaces of an extracorporeal circuit results in extensive alterations in platelet function. These platelet abnormalities have been reproduced in vitro by recirculating heparinized (5 units/ml) human blood at 37 degrees C in a silicone rubber circuit (0.1 m2) containing a spiral coil membrane oxygenator (0.9 m2). During control recirculation trials, platelet counts fell to 29% +/- 8% (mean +/- standard error of the mean) of initial levels within 30 minutes, and sensitivity to the soluble agonists, adenosine diphosphate and epinephrine, disappeared. Plasma levels of the platelet- specific protein platelet factor 4 rose to 2,600 +/- 200 ng/ml, indicating extensive platelet granule release. Similarly, plasma concentrations of thromboxane B2 rose from less than or equal to 100 pg/ml to 500 +/- 200 pg/ml at 120 minutes, and transmission electron microscopy demonstrated disruption of platelet subcellular architecture. In contrast, when ilioprost, a stable prostacyclin derivative (1 ng/ml), was added to the circuit prior to recirculation, the thrombocyte count remained at 85% +/- 4% of initial values. Platelets incubated or recirculated for 2 hours in the presence of iloprost responded normally to both adenosine diphosphate and epinephrine after separation from the drug by gel-filtration. Furthermore, plasma concentrations of platelet factor 4 remained below 300 ng/ml, plasma levels of thromboxane B2 failed to reach detectable levels, and platelet ultrastructure remained intact. Thus, iloprost effectively preserves the circulating platelet count, prevents platelet granule release, and preserves platelet functional and morphological integrity during simulated extracorporeal circulation.

This article has been cited by other articles:

				G. M. Palatianos, C. N. Foroulis, M. I. Vassili, P. Matsouka, G. M. Astras, G. H. Kantidakis, E. Iliopoulou, and E. N. Melissari Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost J. Thorac. Cardiovasc. Surg., February 1, 2004; 127(2): 548 - 554. [Abstract] [Full Text] [PDF]

				J. A. Hyde, J. A Chinn, and T. R Graham Platelets and cardiopulmonary bypass Perfusion, December 1, 1998; 13(6): 389 - 407. [PDF]

				R. L. Korn, C. A. Fisher, E. R. Livingston, N. Stenach, S. J. Fishman, V. Jeevanandam, and V. P. Addonizio THE EFFECTS OF CARMEDA BIOACTIVE SURFACE ON HUMAN BLOOD COMPONENTS DURING SIMULATED EXTRACORPOREAL CIRCULATION J. Thorac. Cardiovasc. Surg., May 1, 1996; 111(5): 1073 - 1084. [Abstract] [Full Text]

				A. Bernabei, N. Gikakis, M. A. Kowalska, S. Niewiarowski, and L. Henry Edmunds Jr Iloprost and echistatin protect platelets during simulated extracorporeal circulation Ann. Thorac. Surg., January 1, 1995; 59(1): 149 - 153. [Abstract] [PDF]

				L. E. Samuels, A. Shektman, G. Amrom, R. J. DiGiovanai, J.-R. Dupont, and M. D. Kerstein Heparin-Induced Thrombocytopenia: A Spectrum of Hemorrhage and Thrombosis--Case Presentations Vascular and Endovascular Surgery, September 1, 1992; 26(7): 596 - 604. [Abstract] [PDF]

				D. Pearson Bleeding following open-heart surgery Perfusion, January 1, 1990; 5(1_suppl): 53 - 56. [PDF]

				D. He and L. Hou Effects of high dose ascorbic acid on haemostasis during and after cardiopulmonary bypass Perfusion, October 1, 1988; 3(4): 281 - 286. [Abstract] [PDF]

				B. P Bidstrup Review article : Blood conservation in cardiac surgery: can drugs help? Perfusion, July 1, 1988; 3(3): 171 - 177. [PDF]

				T. Spyt, D. Wheatley, I. Walker, J. Davidson, K. MacArthur, and W. Martin Placebo-controlled study of Iloprost (ZK 36374) in cardiopulmonary bypass surgery Perfusion, July 1, 1988; 3(3): 179 - 186. [Abstract] [PDF]

				K. Taylor Review article : Vasopressor release and multiple organ failure in cardiac surgery Perfusion, January 1, 1988; 3(1): 1 - 16. [PDF]

				C. Blauth, A. Brady, J. Arnold, J. Brannan, W. Schulenburg, R. Frackowiak, and K. Taylor A double blind clinical trial of Iloprost during cardiopulmonary bypass Perfusion, October 1, 1987; 2(4): 271 - 276. [Abstract] [PDF]

				K. Taylor Review article : Prostacyclin therapy during cardiopulmonary bypass is it beneficial? Perfusion, January 1, 1987; 2(1): 1 - 7. [PDF]

				W. M. DeCampli, D. Goodwin, J. C. Kosek, C. E. Handen, R. S. Mitchell, and D. C. Miller Pharmacological, Hematological, and Physiological Effects of a New Thromboxane Synthetase Inhibitor (CGS-13080) During Cardiopulmonary Bypass in Dogs Ann. Thorac. Surg., December 1, 1986; 42(6): 690 - 696. [Abstract] [PDF]